Dicerna Inks Deal With Ipsen, Second RNAi Partnership of 2010

Posted: April 4, 2010 at 8:11 am

Story Summary: The Watertown, MA-based developer of RNA interference drugs is announcing today it has formed a new alliance with Paris-based Ipsen. Financial terms of the deal arent being disclosed, although it ends up being net-neutral to Dicerna, says chief business officer Martin Williams. Dicerna, avid readers may recall, made some noise on the first business day of 2010 when it announced its first major partnership with Japan-based Kyowa Hakko Kirin. Like other RNAi contenders such as Cambridge, MA-based Alnylam Pharmaceuticals, Dicerna is seeking to specifically silence disease-related genes in ways that havent been possible before with conventional small-molecule drugs or biologically-derived antibodies and other proteins. Dicerna seeks to differentiate itself from the RNAi pack with drug molecules that are a little longer than so-called small interfering RNA molecules, and which interact with a different enzyme. This is supposed to allow for drugs with greater potency, and to provide flexibility with using different modes of delivery into cells. Back in January, CEO Jim Jenson offered a preview of coming attractions when he said he hoped to nail down a $25 million Series B venture financing. That deal is still expected to close in the first half of this year, Williams says….Read the Full Story

Related posts:

  1. Archemix and Dicerna to Collaborate on Conjugated Aptamer-Dicer Substrate RNAi Therapeutics
  2. Dicerna Pharmaceuticals and Ipsen Enter into an Exclusive Research Collaboration for the Development of New Therapeutic Agents in Endocrinology and Oncology
  3. Dicerna Pharmaceuticals to Present at Upcoming RNAi-Focused Scientific Conferences

Related Post

Comments are closed.